Datamonitor estimates the antidyslipidemic drug-treated population at 73.5 million patients across the seven major markets, with the majority having high cholesterol as opposed to hypertriglyceridemia alone. Statins are the dominant treatment for high cholesterol while fibrates are more used for hypertriglyceridemia. Lipid control is an unmet need in a high proportion of drug-treated patients.
Features and benefits
Highlights
Not all patients are available for drug therapy due to the low diagnosis rate, low compliance rates, and therapeutic lifestyle management as the first line of treatment. Only 43% of dyslipidemia patients are reported diagnosed within the seven major markets.
The type of dyslipidemia that a patient is diagnosed with impacts on the treatment regimen used. Statin monotherapy dominates where the target lipid is low-density lipoprotein cholesterol. This is due to statins’ superior proven efficacy in lowering both target lipid levels and cardiovascular disease risk.
Three months after the Lipitor went off patent in the US, primary care physicians were prescribing generics to 35% of their atorvastatin-treated patients, with some patients being switched from other branded statin Crestor. Brand erosion is likely to increase with further generic competition.
Your key questions answered
Released On: 9/3/2012
Views: 3124
Released On: 8/31/2012
Views: 3858
Released On: 8/27/2012
Views: 2139
Released On: 8/23/2012
Views: 2993
Released On: 8/23/2012
Views: 2018
Released On: 8/21/2012
Views: 2711
Released On: 8/16/2012
Views: 3351
Released On: 8/16/2012
Views: 1968
Released On: 8/16/2012
Views: 4217
Released On: 8/14/2012
Views: 2093
Released On: 8/14/2012
Views: 1797